Lower Finasteride Side Effects: Micro-Dosing vs Topical — What works best?

Key takeaways on managing finasteride side effects (micro-dosing vs topical)

If side effects occur

• Temporarily stop finasteride until symptoms resolve.
• Expect resolution to take time:
  • Typically weeks
  • Sometimes months
• The speaker reports they haven’t seen “post-finasteride syndrome” persist clinically, though they acknowledge it may be possible in some individuals.

How to reduce risk after symptoms improve

• Restart at a smaller oral dose once side effects resolve.
• A commonly mentioned strategy is 0.5 mg every other day.
• Monitor two outcomes:
  • Hair stability
  • Ongoing side effects

---

Micro-dosing (oral finasteride) vs switching to topical

• The speaker generally recommends exhausting oral options first, including reduced-dose strategies, before switching to topical.
• Topical finasteride is described as an option for a smaller subset of people who are unwilling to take oral medication.

---

Topical finasteride: key cautions

Efficacy varies by formulation

• Commonly studied strengths are around 0.25%–0.3%, described as generally weaker than oral regimens.
• Some topical products (e.g., higher-strength slow-release gels around ~2.5%) can still be strong enough to suppress DHT similarly to pills.
• As a result, people may still experience side effects if they:
  • apply enough product, or
  • overapply (e.g., multiple times per day)

Delivery method matters

• Sprays may fail to deliver effectively to the scalp if hair is long, since product can cling to hair shafts.
• A better technique suggested:
  • Part the hair
  • Apply directly to the scalp surface
• The speaker prefers using a dropper over a spray for more reliable delivery.

---

Practical reasoning offered

• Oral dosing is described as:
  • Easier for consistency
  • Often better for efficacy
  • Generally better for compliance than scalp-application routines

---

Presenters / sources

• Presenters: Not explicitly named in the subtitles (the speaker refers to themselves as a clinician; another participant asks questions, but names aren’t provided).
• Research mentioned: “Kas Kazarini” studies, including evaluation of higher-strength topical (e.g., ~2.5%) dosing and comparisons of DHT suppression.
• Organizations/products referenced: “HMS” (mentioned in relation to a spray formulation).